ALT-100 (Human IgG1) is a humanized IgG1 monoclonal neutralizing antibody targeting extracellular nicotinamide phosphoribosyltransferase (eNAMPT). This product binds specifically to eNAMPT, blocking its function as a damage-associated molecular pattern (DAMP) that induces pro-inflammatory and pro-fibrotic signaling. ALT-100 effectively inhibits eNAMPT-mediated TLR4 activation, reduces the release of inflammatory cytokines, and suppresses tissue remodeling. It serves as an important pharmacological tool for researching post-infarct myocardial fibrosis, acute respiratory distress syndrome (ARDS), and systemic inflammatory response syndrome.